Multi-proteomic Analysis Revealed Distinct Protein Profiles in Cerebrospinal Fluid of Patients Between Anti-NMDAR Encephalitis NORSE and Cryptogenic NORSE
- PMID: 36224320
- DOI: 10.1007/s12035-022-03011-1
Multi-proteomic Analysis Revealed Distinct Protein Profiles in Cerebrospinal Fluid of Patients Between Anti-NMDAR Encephalitis NORSE and Cryptogenic NORSE
Abstract
New-onset refractory status epilepticus (NORSE) is rare but intractable. Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis and cryptogenic etiologies are the two major causes of NORSE with distinct clinical features. To elucidate the underlying mechanisms, 6 patients with anti-NMDAR encephalitis NORSE and 5 with cryptogenic NORSE (C-NORSE) were enrolled. Five patients of cerebrovascular disorders were used as controls. Quantitative proteomic analysis of the cerebrospinal fluid (CSF) samples of the patients revealed 101 and 56 proteins were changed, respectively. The average fold-change of the upregulated proteins, namely up-proteomic score in this study, was positively correlated with the severity and prognosis of the diseases, including ICU stay (r = 0.9308, P = 0.0035 in NMDAR group; r = 0.8977, P = 0.0193 in C-NORSE group), mRS score at discharge (r = 0.9710, P = 0.0111 in NMDAR group; r = 0.7071, P = 0.2000 in C-NORSE group), and time taken for patients awaking from a coma (r = 0.8823, P = 0.0100 in NMDAR group; r = 0.7906, P = 0.2000 in C-NORSE group). Pathways involved in humoral immune response, wound healing, and epigenetic regulation of transcription were upregulated in anti-NMDAR encephalitis NORSE. Pathways of innate and lymphocyte mediated immune response, synaptic functions, ubiquitination, and cell apoptosis were up-regulated in C-NORSE, which was consistent with a mouse model of status epilepticus. Fc receptor and B cell mediated immunity signaling pathways were downregulated in C-NORSE. Immunome microarray analysis demonstrated high autoantibody targeting 48 proteins in CSF samples of anti-NMDAR encephalitis NORSE. While the reaction was kept at a very low level in C-NORSE. There is no significant difference in inflammatory cytokine level between each group. The level of IL-4 (r = 0.7435, P = 0.0451), IL-13 (r = 0.7643, P = 0.0384), IFN-γ (r = 0.7973, P = 0.0287) and TNF-α (r = 0.8598, P = 0.0141) in NMDAR group, and IL-6 (r = 0.8479, P = 0.0348), IL-8 (r = 0.9076, P = 0.0166) in C-NORSE group were positively correlated with the up-proteomic score. The present study suggests that the up-proteomic score of CSF could be a promising indicator for assessment of the severity of anti-NMDAR encephalitis NORSE and C-NORSE. The distinct CSF proteomes imply different pathogenic mechanisms of the two diseases, and immunotherapy strategies as well.
Keywords: Anti-NMDAR encephalitis; Cerebrospinal fluid proteome; Cryptogenic-NORSE; Immune response; Neurodegeneration; Status epilepticus.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Identification of cerebrospinal fluid biomarker candidates for anti-N-methyl-D-aspartate receptor encephalitis: High-throughput proteomic investigation.Front Immunol. 2022 Oct 26;13:971659. doi: 10.3389/fimmu.2022.971659. eCollection 2022. Front Immunol. 2022. PMID: 36389787 Free PMC article.
-
Cerebrospinal fluid light and heavy neurofilament level increased in anti-N-methyl-d-aspartate receptor encephalitis.Brain Behav. 2019 Aug;9(8):e01354. doi: 10.1002/brb3.1354. Epub 2019 Jul 17. Brain Behav. 2019. PMID: 31313506 Free PMC article.
-
Higher CSF Levels of NLRP3 Inflammasome Is Associated With Poor Prognosis of Anti-N-methyl-D-Aspartate Receptor Encephalitis.Front Immunol. 2019 May 31;10:905. doi: 10.3389/fimmu.2019.00905. eCollection 2019. Front Immunol. 2019. PMID: 31214158 Free PMC article.
-
Cytokine/chemokine levels in the CSF and serum of anti-NMDAR encephalitis: A systematic review and meta-analysis.Front Immunol. 2023 Jan 23;13:1064007. doi: 10.3389/fimmu.2022.1064007. eCollection 2022. Front Immunol. 2023. PMID: 36761173 Free PMC article.
-
Diagnostic value of CSF findings in antibody-associated limbic and anti-NMDAR-encephalitis.Seizure. 2013 Mar;22(2):136-40. doi: 10.1016/j.seizure.2012.12.013. Epub 2013 Jan 11. Seizure. 2013. PMID: 23318046 Review.
Cited by
-
Identification of Central Nervous System Oncologic Disease Biomarkers in EVs from Cerebrospinal Fluid (CSF) of Pediatric Patients: A Pilot Neuro-Proteomic Study.Biomolecules. 2023 Nov 30;13(12):1730. doi: 10.3390/biom13121730. Biomolecules. 2023. PMID: 38136601 Free PMC article.
-
Interleukin-6 in epilepsy and its neuropsychiatric comorbidities: How to bridge the gap.World J Psychiatry. 2025 Jan 19;15(1):100297. doi: 10.5498/wjp.v15.i1.100297. eCollection 2025 Jan 19. World J Psychiatry. 2025. PMID: 39831011 Free PMC article.
-
Cytokines in new-onset refractory status epilepticus: ready for clinical use?Acta Epileptol. 2024 Jul 1;6(1):19. doi: 10.1186/s42494-024-00163-6. Acta Epileptol. 2024. PMID: 40217433 Free PMC article.
-
CSF Tau Is a Biomarker of Hippocampal Injury in Cryptogenic New-Onset Refractory Status Epilepticus.Ann Clin Transl Neurol. 2025 May;12(5):1054-1064. doi: 10.1002/acn3.70043. Epub 2025 Mar 31. Ann Clin Transl Neurol. 2025. PMID: 40164513 Free PMC article.
-
Identifying the Anti-inflammatory Effects of Astragalus Polysaccharides in Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Network Pharmacology and Experimental Validation.Comb Chem High Throughput Screen. 2024;27(7):1022-1032. doi: 10.2174/1386207326666230816162113. Comb Chem High Throughput Screen. 2024. PMID: 37587811
References
-
- Vezzani A, Dingledine R, Rossetti AO (2015) Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. Expert Rev Neurother 15(9):1081–1092. https://doi.org/10.1586/14737175.2015.1079130 - DOI
-
- Mantoan Ritter L, Nashef L (2021) New-onset refractory status epilepticus (NORSE). Pract Neurol 21(2):119–127. https://doi.org/10.1136/practneurol-2020-002534 - DOI
-
- Hirsch LJ, Gaspard N, van Baalen A, Nabbout R, Demeret S, Loddenkemper T, Navarro V, Specchio N et al. (2018) Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 59(4):739–744. https://doi.org/10.1111/epi.14016 - DOI
-
- Gaspard N, Foreman BP, Alvarez V, Kang CC, Probasco JC, Jongeling AC, Meyers E, Espinera A et al. (2015) New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology 85(18):1604–1613. https://doi.org/10.1212/WNL.0000000000001940 - DOI
-
- Iizuka T, Kanazawa N, Kaneko J, Tominaga N, Nonoda Y, Hara A, Onozawa Y, Asari H et al. (2017) Cryptogenic NORSE: its distinctive clinical features and response to immunotherapy. Neurol Neuroimmunol Neuroinflamm 4(6):e396. https://doi.org/10.1212/NXI.0000000000000396 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources